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A B S T R A C T
The Cdc28 protein kinase subunits, Cks1 and Cks2, play dual roles in Cdk-substrate speciﬁcity and Cdk-in-
dependent protein degradation, in concert with the E3 ubiquitin ligase complexes SCFSkp2 and APCCdc20. Notable
targets controlled by Cks include p27 and Cyclin A. Here, we demonstrate that Cks1 and Cks2 proteins interact
with both the MllN and MllC subunits of Mll1 (Mixed-lineage leukaemia 1), and together, the Cks proteins deﬁne
Mll1 levels throughout the cell cycle. Overexpression of CKS1B and CKS2 is observed in multiple human cancers,
including various MLL-rearranged (MLLr) AML subtypes. To explore the importance of MLL-Fusion Protein
regulation by CKS1/2, we used small molecule inhibitors (MLN4924 and C1) to modulate their protein de-
gradation functions. These inhibitors speciﬁcally reduced the proliferation of MLLr cell lines compared to pri-
mary controls. Altogether, this study uncovers a novel regulatory pathway for MLL1, which may open a new
therapeutic approach to MLLr leukaemia.
1. Introduction
The Cks proteins are small phospho-adapters required for correct
CDK substrate recognition (but not kinase activity), and more precisely,
for the speciﬁcation of multisite phosphorylation [1,2]. Further Cks
functions in transcription and protein degradation have been reported
in yeast [3,4] and mammals [5–7]. Indeed, it has been shown that Cks1
and Cks2 associate with two ubiquitin E3 ligase complexes, SCFSkp2 and
APCCdc20, thereby regulating degradation of Cyclin A and the CDK in-
hibitor p27 [7,8]. Despite redundant functions between Cks1 and Cks2
[5,9–11], sequence divergence in the Skp2-binding region results in
opposing roles during degradation of the Skp2 target p27. Indeed, Cks1
brings p27 to Skp2, facilitating p27 ubiquitination and degradation,
while Cks2 protects p27 from Skp2 interactions and stabilises p27
[7,8,12]. Whereas both Cks1−/− and Cks2−/− mice are viable [7,13],
the Cks1 and Cks2 double knockout is embryonic lethal after the morula
stage, indicating that Cks1 and Cks2 are essential for embryonic
development [5]. Although many Cks1−/− and Cks2−/− mouse model
phenotypes are due to altered p27 regulation, loss of Cks1 in Eμ-Myc
transgenic mice (a model of human Burkitt's lymphoma) reduces cancer
progression independent of p27 regulation [14], demonstrating a role
for Cks1 beyond p27 regulation. In further studies of their tumorigenic
potential, Cks1 and Cks2 have not only been described to be under the
control of c-Myc, but also of B-RAF and Cyclin D1 oncoproteins [15].
Moreover, CKS1B and CKS2 are frequently overexpressed in various
cancers [16–19], including multiple myeloma [20,21] and breast
cancer [6,22,23], correlating with increased proliferation and poor
prognosis.
MLL1 is a histone methyltransferase, which modulates a gene ex-
pression signature important for embryonic and haematopoietic stem
cell development [24–26]. The MLL1 protein is cleaved by Taspase 1
into N-terminal (MLLN) and C-terminal (MLLC) fragments [27,28],
which require phosphorylation and inter-molecular interaction for full
activity [27,29]. Furthermore, bimodal degradation of MLL1 by the
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SCFSKP2 and APCCDC20 complexes results in a cell cycle-dependent, bi-
phasic expression proﬁle [30]. The human MLL1 gene is chieﬂy known
for its involvement in chromosomal translocations driving mixed-
lineage leukaemias [31]. Leukaemic rearrangements fuse the N-term-
inal portion of MLL1 with a variety of translocation partners to produce
a mature MLL-Fusion Protein (MLL-FP), which consequently omits the
MLL1 C-terminal domains [32,33]. Common MLL1 translocation part-
ners include AFF1/AF4, MLLT4/AF6, MLLT3/AF9, MLLT10/AF10, ELL,
and MLLT1/ENL [34]. Mechanistically, MLL-FPs show diminished in-
teractions with the SCFSKP2 and APCCDC20 complexes, resulting in their
stabilisation [30], and the building of diverse transcriptional com-
plexes, which override the normal histone methyltransferase activity of
MLL1 [28]. These alterations lead to stable expression of devel-
opmentally important target genes (e.g. Hox genes), and aberrant ac-
tivation of various signalling pathways [35]. Additionally, stabilisation
of wild-type (WT) MLL1 protein in MLLr cell lines has been revealed as
an important route for competing with, and suppressing the onco-
genicity of, MLL-FPs [36]. MLL-rearranged (MLLr) leukaemias are
currently treated by chemotherapy, but with 5 year survival rates below
50% and 20% in paediatric and adult cases respectively, there is a
critical need for more eﬀective therapies [37].
In this study, we identiﬁed Mll1 as a Cks1/Cks2 interactor and show
that Mll1 stability is controlled by the Cks proteins. Collectively, our
data demonstrates a role for Cks proteins in the regulation of Wnt
signalling through Mll1. This previously unknown role for the CKS1/
CKS2 axis has consequences for normal MLL1 function but, un-
expectedly, also for MLL-FP leukaemic activity. These ﬁndings oﬀer a
new potential therapeutic target for the treatment of poor prognosis
acute leukaemias.
2. Materials and methods
2.1. Cell culture and patient samples
Mouse Embryonic Fibroblasts (MEFs) were isolated from day E13.5
embryos, and cultured in DMEM supplemented with 10% Foetal Bovine
Serum (FBS) and 5% penicillin/streptomycin (ThermoScientiﬁc,
Loughborough, UK) as previously described [8], and were sponta-
neously immortalised by the 3T3 protocol. In accordance with pre-
viously reported data [8], we conﬁrmed that Cks1−/− MEFs have a
slower cell cycle, increased G1 phase population and p27 protein level
when compared to wild-type (WT) control. Conversely, Cks2−/− MEFs
cycle faster, with an increased S phase population, lower p27
protein level and increased γH2AX level when compared to WT control
(Fig. S1).
ML-2 (DSMZ, Braunschweig, Germany; ACC15), THP-1 (DSMZ;
ACC16), KOPN-8 (DSMZ; ACC552), ML-1, and RS4; 11 cell lines and
peripheral blood mononuclear cells (PBMCs) [38,39] were cultured in
RPMI 1640 (ThermoScientiﬁc) with 10% FBS and 5% penicillin/strep-
tomycin.
Diagnostic peripheral blood or bone marrow cDNA samples were
obtained from the MLL Munich Leukemia Laboratory. PBMCs and cord
blood mononuclear cells were obtained from healthy donors and se-
parated using Ficoll-Paque Plus as per the manufacturer's instructions
(GE Healthcare, Amersham, UK). CD34+ cells were isolated using the
EasySep Human CD34 positive selection kit (Stem Cell Technologies,
Cambridge, UK), and cultured in StemSpan SFEM II medium for ex-
pansion supplemented with hSCF (300 ng/ml), hTPO (20 ng/ml) and
hFLT3L (300 ng/ml) for optimal proliferation (Peprotech, London, UK).
RT-qPCRs were performed according to standard Europe Against
Cancer conditions [40].
2.2. Cell cycle synchronisation
MEFs were synchronised in G1 phase by serum starvation (1% FBS),
in S phase by double thymidine block (2 mM thymidine; Sigma-Aldrich,
Dorset, UK), and in M phase by nocodazole block (40 ng/μl nocodazole;
Merck Millipore, Watford, UK) for 12 h.
2.3. Cell transfection
All cells were transfected by nucleofection using the Amaxa nu-
cleofector system (Lonza, Slough, UK) with either plasmid DNA (0.5-
2 μg) or siRNA (0.5-1 μM). MEFs were transfected using the P4 Primary
Cell Kit and program CZ-167, and MLL-translocation cell lines using the
Cell Line kit L and program A-020. The FLAG-MLL1 plasmid was a kind
gift from Prof. Thomas Milne. All RNA interference knockdowns were
performed with two independent siRNAs, and siRNA sequences are as
follows: Non-Targeting Control (Mouse) 5′-UGGUUUACAUGUCG-
ACUAA-3′, 5′-UGGUUUACAUGUUGUGUGA-3′, 5′-UGGUUUACAUG-
UUUUCCUA-3′, 5′-UGGUUUACAUGUUUUCUGA-3′ Dharmacon (D-
001810-10-20); Mll1 (11) 5′-GCACAGUGGUCUCACGAUU-3′
Dharmacon (J-040631-10); Mll1 (14) 5′-CUGUUGAAUUCUCGGACUA-
3′ Dharmacon (J-040631-11); Non-Targeting Control (Human) 5′-
UGGUUUACAUGUCGACUAA-3′, 5′-UGGUUUACAUGUUGUGUGA-3′,
5′-UGGUUUACAUGUUUUCCUA-3′, 5′-UGGUUUACAUGUUUUCUGA-3′
Dharmacon (D001810-10-20); CKS1B (A) 5′-CGACGAGGAGUUU-
GAGUAUUU-3′ [6]; CKS1B (B) 5′-ACCAGAACCUCACAUCUUGUU-3′
[6]; CKS2 (A) 5′-CUGCAAGUAGGUUACUGUA-3′ [18]; CKS2 (B) 5′-
GUUUGUAUGUUGCAUUUAATT-3′ [11].
2.4. Immunoﬂuorescent staining, ImageStreamX and confocal microscopy
For ImageStreamX analysis, cells were ﬁxed in 4% paraformalde-
hyde, permeabilised in 0.5% Triton X-100, and incubated overnight
with a pan-β-catenin antibody (Cell Signalling Technology, Hitchin, UK
(CST; #8480)) followed by anti-Rabbit-FITC (ThermoScientiﬁc). Cells
were resuspended in PBS containing 2 mM EDTA and 5 μg/ml DAPI.
Stained cells were analysed on an ImageStreamX Mark II imaging ﬂow
cytometer using the INSPIRE application (Amnis, Seattle, WA, USA).
Analysis was carried out using the IDEAS software (Amnis). Cells were
selected as follows: Single cells, Focused cells, Double positive (β-ca-
tenin/DAPI). Final selected cells were analysed using the feature and
mask: Similarity_Object(M01,Brightﬁeld,Tight)_β-catenin_DAPI, which
calculates Similarity (logarithmic transformation of Pearson's correla-
tion coeﬃcient) for β-catenin and DAPI co-localisation within the cell
[41] (Fig. S3). A minimum of 10,000 cells was present in the ﬁnal gate
(double positive). Fisher's discriminant ratio (Rd Median) was calcu-
lated to measure nuclear translocation of β-catenin as follows: Rd =
(Median sample−Median negative control)/(Median absolute devia-
tion sample + Median absolute deviation negative control). Confocal
microscopy for γH2AX was carried out as previously described [8].
2.5. Real-time quantitative PCR
Total cellular RNA was extracted from cells using the RNeasy Mini
Kit (Qiagen, Crawley, UK), with on-column DNase I digestion, as per the
manufacturer's instructions. Quantitative PCR analyses were carried out
using either the Quantitect SYBR Green RT-PCR kit (MEFs – Qiagen) or
the TaqMan Universal PCR Master Mix kit (MLL-translocation cell lines
– ThermoScientiﬁc). All SYBR Green and TaqMan assays were run on a
7900HT Real-Time PCR system (Applied Biosystems, UK). Primers are
listed in Table S1.
2.6. TCF/LEF reporter assays
Both MEFs andMLL-translocation cell lines were co-transfected with
5 μg M50 Super 8x TOPFlash (#12456; Addgene) or control M51 Super
8x FOPFlash (#12457; Addgene) and 100 ng Renilla control (pRL-TK;
Promega, Southampton, UK). Luciferase activity was measured using
the Dual Luciferase Assay System (Promega). Relative Luciferase
Activity (RLA) was calculated as Luciferase/Renilla signal.
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2.7. Cell viability and apoptosis assays
Cells were seeded in triplicate in 96-well plates (1 × 105 cells/ml)
with or without diﬀerent concentrations of inhibitor (SKP2 E3 Ligase
Inhibitor C1 or NAE inhibitor MLN4924; Merck Millipore). Cell viabi-
lity was assessed using AlamarBlue (ThermoScientiﬁc), according to the
manufacturer's instructions, 48 h post-treatment.
For the evaluation of apoptosis, cells were stained with Annexin V-
FITC and PI (Biolegend, London, UK) following manufacturer's in-
structions. A minimum of 20,000 cells were assayed for each condition
on a ﬂow cytometer (BD Canto), and analysed using FlowJo software
(Tree Star, Switzerland).
2.8. Cell cycle analysis
Cells were pulsed with 10 μM EdU for 60 min, and ﬁxed in 4%
paraformaldehyde. EdU incorporation was assessed with the Click-iT
EdU AlexaFluor 647 kit (ThermoScientiﬁc), following manufacturer's
instructions. At least 20,000 cells were acquired using a BD Canto ﬂow
cytometer and analysed with FlowJo software.
2.9. Immunoblot analysis
Nuclear and cytoplasmic extracts were prepared using the
ThermoScientiﬁc NER kit as per manufacturer's instructions. Whole cell
extracts were prepared using RIPA buﬀer. Western blots of MLLN and
MLLC subunits were carried out on NuPAGE 3–8% Tris-Acetate gels
(ThermoScientiﬁc) as per the manufacturer's instructions.
Primary antibodies used in this study were as follows: H3 (06-755)
and γH2AX (JBW301) (Merck Millipore); Actin (#3700), pan-β-catenin
(#8480), Tubulin (#2128), Pin1 (#3722), phospho-AKT Ser473
(#4060) and AKT (#4691) (CST); p27 (610241) (BD Biosciences,
Oxford, UK); MLL1 (A300-086A), AF9 (A300-596A), AF6 (A302-199A)
and ENL (A302-268A) (Bethyl, UK); MLLC (sc-374,392), pan-Cks (sc-
6238), CDK2 (sc-163), Cleaved-Caspase 3 (sc-7272) and normal IgG
(Santa Cruz, CA, USA); and Cks1 (37-0200) and Cks2 (37-0300)
(ThermoScientiﬁc).
2.10. Co-immunoprecipitation assay
Whole cell lysates were pre-cleared with protein G sepharose beads
(GE Healthcare), and incubated overnight at 4 °C under constant rota-
tion, with either anti-FLAG M2 aﬃnity gel (A2220; Sigma-Aldrich) or
protein G sepharose beads with the relevant antibody. 2% of each pre-
cleared sample was kept as input control. Beads were washed in RIPA
buﬀer, and protein complexes were eluted with 3X FLAG peptide
(F4799; Sigma-Aldrich) or in Laemmli buﬀer.
2.11. Colony formation assay
Indicated cell numbers were plated in 2 ml cytokine supplemented
methylcellulose (Methocult H4434, Stem Cell Technologies) and in-
cubated for 14 days before scoring for presence of phenotypic colonies
according to the manufacturer's instructions.
3. Results
3.1. Cks1 and Cks2 control Mll1 protein levels and inﬂuence Mll1-
dependent gene expression
The ﬁrst evidence that the Mll1 protein may be under the control of
the Cks1/Cks2 axis is based on Mll1 biphasic, cell-cycle dependent
regulation by the SCFSkp2 and APCCdc20 ubiquitin E3 ligase complexes,
both of which require Cks for degradation of a portion of their known
targets. Further to this, in silico analysis revealed that Mll1 contains
multiple putative Cks1 minimum consensus sites ([FILPVWY]xTP) on
both N- and C-terminal subunits [2,42]. To investigate whether Mll1
protein levels, similar to p27 [8], are controlled by the Cks1/Cks2 axis,
we used WT, Cks1−/− and Cks2−/− MEFs (Fig. S1), that were syn-
chronised in G1, S and M phases of the cell cycle, to analyse Mll1 ex-
pression at both the RNA and protein levels (Fig. 1A-B). Mll1 transcript
abundance was signiﬁcantly altered in S phase for both Cks1−/− (> 2-
fold higher; p = 0.011) and Cks2−/− (≥2-fold lower; p = 0.012)
compared to WT. The same trend was observed in asynchronous cells,
however, only the increased mRNA levels in Cks1−/− MEFs was sig-
niﬁcantly diﬀerent from control levels (≥1.5-fold higher; p = 0.016;
Fig. 1A).
Mll1 protein levels do not directly correlate with mRNA levels, and
the predominant route of Mll1 regulation has been reported to be via
protein degradation [30]. To examine whether Cks proteins modulate
Mll1 protein stability, we used western blotting to compare the levels of
both MllN and MllC subunits in Cks1−/− and Cks2−/− MEFs. This re-
vealed increased MllN as well as MllC levels in Cks1−/− MEFs, both in
asynchronous cells and at synchronised cell cycle stages. The relative
increase was most striking in G1 and M phase cells and less pronounced
in S phase cells. In contrast, both Mll1 subunits were almost un-
detectable in Cks2−/− cells when compared to WT controls (Fig. 1B).
Remarkably, this is reminiscent of the cell cycle regulator p27, whose
degradation by SCFSkp2 is promoted by Cks1 and is protected from
degradation by Cks2 [8].
To determine whether Cks proteins directly interact with Mll1 to
inﬂuence its stability, or this eﬀect was an indirect downstream con-
sequence of Cdk activity changes (e.g. as seen for γH2AX [8]), we
performed co-immunoprecipitation assays. WT MEFs overexpressing
FLAG-tagged Cks1 or Cks2 were lysed and incubated with FLAG-con-
jugated agarose beads, to pull down Cks proteins. In these conditions,
Cks1 and Cks2 were consistently found to pull down both MllN and MllC
subunits (Fig. 1C). Altogether, these results strongly suggest that Cks
proteins regulate Mll1 protein levels in a fashion analogous to their
opposing roles in p27 degradation. Indeed, Cks1 would promote Mll1
degradation, while Cks2 would act to stabilise Mll1 by protecting it
from Cks1-mediated degradation.
The histone methyltransferase function of Mll1 is critical for pro-
moting transcription of an array of target genes, with Mll1−/− MEFs
showing signiﬁcant reductions in expression of these target genes
compared to WT controls [26]. Comparison of WT versus Cks1−/− or
Cks2−/− total RNA, from asynchronous and synchronised cells, re-
vealed major alterations in those Mll1 target genes deﬁned by Wang
et al. [26] as most frequently downregulated (e.g. Dkk3, Thbd, Hoxc9
and Mgp; Fig. 1D). Interestingly, the diﬀerences in Mll1 target genes
underlined the overlapping and independent functions of Cks1 and
Cks2. Whereas the changes in Dkk3, Thbd, Rspo and Mgp were similar
between Cks1−/− and Cks2−/− cells, a subset of Mll1 target genes (e.g.
Sfrp1, Tgfbi and Ebf3) was diﬀerentially regulated between Cks
knockout cells. This indicates that the alteration of Mll1 protein levels
in Cks-deﬁcient MEFs has a direct impact on the primary cellular
function of Mll1.
3.2. Opposing roles of Cks1 and Cks2 in Wnt signalling through Mll1
regulation
A subset of Mll1 target genes (e.g. Sfrp1, Rspo2), which are sig-
niﬁcantly altered in Cks-deﬁcient MEFs (Fig. 1D) are key players in the
Wnt signalling pathway. To study Wnt signalling in Cks-deﬁcient MEFs,
we used the TOPFlash reporter assay for β-catenin-induced T-cell
factor/lymphoid-enhancing factor (TCF/LEF) transcriptional activity in
response to Wnt3a, a Wnt ligand commonly used for in vitro studies
[43]. This revealed a signiﬁcant contribution of Cks proteins to TCF/
LEF transcriptional activity (Fig. 2A). Indeed, Cks1−/− MEFs displayed
a signiﬁcantly reduced basal activity compared to WT (p = 0.01), and
were unresponsive to Wnt3a treatment (versus WT p < 0.05). Con-
versely, Cks2−/− MEFs had a similar basal activity level compared to
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the WT control, but showed signiﬁcantly faster induction kinetics and
reached greater maximal TCF/LEF activity in response to Wnt3a
(p < 0.01; Fig. 2A). This demonstrates a complex contribution of the
Cks1/Cks2 axis to Wnt signalling, potentially occurring through Mll1
protein regulation.
To investigate whether the diﬀerent Mll1 levels observed in Cks-
deﬁcient MEFs were responsible for the opposing eﬀects of Cks1 and
Cks2 on Wnt signalling, the same experiment was repeated in MEFs
after manipulation ofMll1 expression (Fig. S2). Overexpression ofMLL1
reduced the induction kinetics and maximal response of TCF/LEF ac-
tivity in response to Wnt3a in WT (p < 0.02 at 16 h and 32 h) and
more strikingly in Cks2−/− (p < 0.01 at 16 h and 32 h; Fig. 2A
+MLL1) MEFs. This is consistent with the possibility that reduced Mll1
levels in Cks2−/− MEFs contributed to increased Wnt signalling. As
expected, since Cks1−/− MEFs already have a greater level of Mll1
compared to WT and Cks2−/− MEFs, Cks1−/− cells were unresponsive
to MLL1 overexpression, and consequently are unable to further repress
Wnt signalling activity. Conversely, siRNA-mediated knockdown of
Mll1 in WT and Cks1−/− cells increased the basal TCF/LEF activity, and
the kinetic of response by Wnt3a, to a small but signiﬁcant and re-
producible degree (Fig. 2A siRNA:Mll1). In Cks2−/− cells, Mll1
knockdown also signiﬁcantly increased sensitivity to Wnt3a (Fig. 2A
siRNA:Mll1). These eﬀects were speciﬁc to Wnt signalling, as no acti-
vation was observed with the FOPFlash negative control construct (data
not shown). The partial restoration of Wnt signalling in Cks1−/− MEFs
by Mll1 knockdown again suggests that Mll1 is a target of Cks proteins,
which impacts on transcriptional regulation and downstream signalling
pathways. Thus, the respective impacts of Cks1 or Cks2 knockout were
partially reversed by readjusting Mll1 protein levels.
A key step during Wnt signal transduction is the translocation of β-
catenin from the cytoplasm to the nucleus [44]. To investigate this
process, we used an imaging ﬂow cytometer to measure the co-
localisation of β-catenin with a nuclear dye [45] (Amnis ImageStreamX
Mk II; Fig. S3). As expected, nuclear β-catenin was signiﬁcantly in-
creased in WT MEFs in response to Wnt3a treatment (p < 0.05;
Fig. 2B-C and Fig. S4). Nuclear translocation of β-catenin in Cks1−/−
cells was signiﬁcantly reduced compared to WT (p < 0.05), with lower
basal nuclear β-catenin and minimal nuclear translocation in response
to Wnt3a. In contrast, Cks2−/− MEFs had a signiﬁcantly higher basal
level of nuclear β-catenin compared to WT (p < 0.05), and were
minimally responsive to Wnt3a, indicating that increased TCF/LEF
activity is partially due to constitutively high nuclear β-catenin
(Fig. 2B). Cell fractionation followed by western blot analysis con-
ﬁrmed decreased nuclear localisation of β-catenin in Cks1−/− MEFs,
and proportionally higher nuclear β-catenin in Cks2−/− MEFs when
compared to WT MEFs (Fig. 2D). As an additional readout for Wnt
signalling, we analysed Akt phosphorylation. Wnt3a treatment caused
Akt phosphorylation to be maintained at its basal level in Cks1−/−, and
to be markedly upregulated in Cks2−/− MEFs when compared to WT
control (Fig. 2E).
Taken together, these data demonstrate that opposing eﬀects of
Cks1 and Cks2 on Mll1 protein levels have a signiﬁcant impact on
cellular Wnt signalling in MEFs.
3.3. Aberrant CKS expression in MLL-rearranged leukaemias
Expression of CKS1B and CKS2 was investigated by RT-qPCR in a
total of 65 patients diagnosed with AML, ALL or CML (Fig. 3A-B). CD34
enriched cord blood mononuclear cells (CD34+) and peripheral blood
mononuclear cells (PBMCs) from healthy donors were used as controls.
CKS1B and CKS2 showed signiﬁcantly increased expression in patient
samples carrying MLL-AF9 (n = 20, CKS1B p = 0.0001, CKS2
p = 0.004), MLL-ENL (n = 8, CKS1B p = 0.0024, CKS2 p = 0.0194),
MLL-AF6 (n = 6, CKS1B p = 0.0155, CKS2 p = 0.0456), MLL-AF4
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diﬀerences (N = 3). (B) Western blots for nuclear extracts of asynchronous and synchronised MEFs. Histone H3 was used as a nuclear loading control. (C) Whole cell lysates from WT
MEFs overexpressing FLAG-tagged Cks1 or Cks2 were immunoprecipitated using FLAG-agarose slurry. Western blots for p27 and Cdk2 were used as positive controls for co-im-
munoprecipitation. * indicates FLAG-tagged Cks. Western blots are representative of 3 independent experiments. (D) Heat map of Mll1 target gene expression in Cks-deﬁcient MEFs. RNA
extracted from asynchronous (Async) and synchronised MEFs was analysed for the top downregulated Mll1 target genes as designated by Wang et al. [26]. Two independent control genes
(Actin and Gapdh) were used to measure relative RNA abundance. Actin controlled values are represented as Log2 fold change expression versus WT control from the same cell cycle stage.
Data analysis was performed using GraphPad Prism 7 software.
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(n = 5, CKS1B p = 0.0165, CKS2 p = 0.0031) and BCR-ABL (n = 20,
CKS1B p = 0.0001, CKS2 p = 0.0002) fusions compared to PBMCs.
CKS1B, but not CKS2, exhibited signiﬁcantly higher expression in pa-
tient samples carrying the MLL-ELL fusion (n = 6, CKS1B p = 0.0128)
compared to PBMCs (Fig. 3A-B). Whereas CKS2 expression in all leu-
kaemic cells tested was similar to CD34+ cells, CKS1B was expressed at
signiﬁcantly higher levels in CD34+ cells than leukaemic patient sam-
ples. These data are in agreement with publicly available datasets,
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including the MILE study [46], which also found signiﬁcantly higher
CKS1B and CKS2 expression in healthy bone marrow mononuclear cells
compared to bulk MLLr leukaemic samples. Altogether, these analyses
revealed a dysregulation of CKS expression in MLLr leukaemia, but also
in BCR-ABL positive CML [47], consistent with putative roles for CKS1B
and CKS2 in leukaemogenesis. CKS expression levels might also be
linked to the relative stage of maturation in normal haematopoiesis
(CD34+ versus PBMC).
3.4. Heterogeneous associations of MLL-FPs with CKS proteins
To determine whether CKS proteins interact with MLL-FPs, co-im-
munoprecipitation assays with antibodies speciﬁc to the MLL-FP (or an
IgG isotype control as a negative control) were performed. Using cell
lines carrying MLL-AF9 (THP-1 – myeloid lineage), MLL-AF6 (ML-2 –
myeloid lineage) and MLL-ENL (KOPN-8 – lymphoid lineage) translo-
cations, the fusion partners were pulled down and western blotted for
endogenous CKS1 and CKS2 (Fig. S5). All fusion partner speciﬁc anti-
bodies were able to immunoprecipitate the endogenous MLL-FPs,
whereas IgG controls were not. When probing for CKS1 and CKS2, the
MLL-AF9 fusion protein was found to retain interactions with both
CKS1 and CKS2 (Fig. S5A). MLL-AF6 retained interaction only with
CKS1 (Fig. S5B), while no interaction could be detected between MLL-
ENL and either CKS1 or CKS2 (Fig. S5C). These results demonstrate that
MLL interaction with CKS proteins is aﬀected by oncogenic fusion
partners in various ways, reinforcing the concept that MLL-FPs shape
distinct protein complexes [28,48].
3.5. MLL fusion partners dictate the roles of CKS proteins in Wnt signalling
Active Wnt signalling is required for the development of leukaemic
stem cells, disease progression, and, in some cases, loss of sensitivity to
chemotherapeutic agents [49–52]. To explore CKS1 and CKS2 Wnt
signalling contributions in MLL-translocation carrying cell lines, we
again used the TOPFlash assay. In agreement with published data, we
found the Wnt signalling pathway to be highly active in KOPN-8 cells
[53] and active, albeit to a lesser extent, in THP-1 cells [54] (Fig. S6A).
CKS1B knockdown signiﬁcantly reduced Wnt signalling in KOPN-8
cells, but had no eﬀect on THP-1 cells (Fig. 4A-B and Figs. S6B-C and
S7). Conversely, CKS2 knockdown signiﬁcantly increased Wnt signal-
ling in THP-1 cells, but had no eﬀect on KOPN-8 cells (Fig. 4A-B).
CKS1B and CKS2 double knockdown produced an intermediate phe-
notype in KOPN-8 cells, but interestingly, further increased Wnt sig-
nalling in THP-1 cells (Fig. 4A-B). It should be noted that RNA inter-
ference targeting CKS1B, CKS2, or a combination of both siRNAs did
not compromise the cell viability or proliferation of THP-1 or KOPN-8
cells (data not shown). Considering that CKS knockdowns were not
highly eﬃcient in THP-1 and KOPN-8 cells (Fig. S7), these data show
the sensitivity to the CKS1/CKS2 axis on the regulation of MLL, and
consequently Wnt signalling in MLL-translocation lines.
3.6. Inhibition of CKS-dependent protein degradation is cytotoxic for MLL-
translocation lines
We next investigated the eﬀect of small molecule inhibitors tar-
geting the Cullin Ring Ligase (CRL) family of protein degradation ma-
chinery, of which CKS1 acts as a constituent. For this purpose, we used
Fig. 2. Wnt signalling alterations in Cks-deﬁcient MEFs are partially rescued by Mll1 alterations. (A) Untreated, MLL1 overexpressing, and Mll1 knockdown MEFs were treated with
50 ng/ml Wnt3a and assayed for relative luciferase activity (RLA) for the indicated time points. Values are represented as fold change RLA versus endogenous WT control. A Student's t-
test was used to determine signiﬁcance of diﬀerences (N = 3). * indicates signiﬁcant diﬀerences versus WT control (p < 0.05). # indicates signiﬁcant diﬀerences versus genotype
speciﬁc control (p < 0.05). (B) WT and Cks-deﬁcient MEFs were transfected with either non-speciﬁc siRNA or siRNA:Mll1 and treated with 50 ng/ml Wnt3a for the indicated time points.
Co-localisation of β-catenin and DAPI was measured within the brightﬁeld image of the cell using the ImageStreamX imaging ﬂow cytometer. Fold change Rd. median versus WT
unstimulated values were calculated using Pearson's correlation coeﬃcient and Fisher's discriminant ratio for β-catenin and DAPI localisation within the cell. Bars represent β-catenin and
DAPI co-localisation when compared to the WT unstimulated cells. A Student's t-test was used to assess signiﬁcance of diﬀerences between samples (N = 3). * indicates signiﬁcant
diﬀerences versus WT control (p < 0.05). # indicates signiﬁcant diﬀerences versus genotype speciﬁc control (p < 0.05). (A-B) RNA interference knockdowns were performed with two
independent siRNAs toMll1. (C) Representative images of β-catenin and DAPI localisation measured using ImageStreamX. (D) Nuclear translocation of β-catenin in response to Wnt3a was
conﬁrmed by western blot with a pan-β-catenin antibody in WT and Cks-deﬁcient MEFs. (E) Measurement of PI3K/Akt pathway activation in whole cell lysates by Akt versus phospho-Akt
western blots, in WT and Cks-deﬁcient MEFs, after Wnt3a treatment for the indicated time points. Actin and Histone H3 were probed for as whole cell fraction and nuclear fraction
controls. Western blots are representative of 3 independent experiments.
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the small molecule inhibitor of the NEDD-8 activating enzyme (NAE),
MLN4924 (or Pevonedistat), which has shown promise for targeting of
protein degradation in cancer therapy, including diﬀuse large B-cell
lymphoma and AML [55,39,56]. We also tested C1, a small molecule
inhibitor of the SKP2-CKS1 degradation complex [57]. These inhibitors
have both been shown to reduce p27 ubiquitination, with implications
for cancer treatment [39,57–60]. Whereas NAE inhibitors stabilise a
broad range of Cullin-RING-based ubiquitin ligase targets (e.g. pIκBα,
CDT-1, p27, p21) [55,39,61], SKP2-CKS1 inhibitors exclusively sup-
press degradation of CKS1-dependent SKP2 targets (e.g. p27), but not of
CKS1-independent SKP2 targets (e.g. p21) [57,58]. MLN4924 treatment
of THP-1 and KOPN-8 cells resulted in a large increase in p27 protein
level, as previously described in a diﬀerent MLL-AF9 cell line [39],
conﬁrming inhibition of the Cullin-containing SCF E3 ligase (Fig. 5A).
In agreement with a previous study in melanoma cells [57], treatment
with the SKP2-CKS1 inhibitor C1 increased p27 protein levels in both
cell lines. Interestingly, inhibitor treatments had opposite eﬀects on
MLL-fusion protein expression levels. Indeed, while KOPN-8 cells ex-
hibited a decrease of MLL-ENL protein expression after MLN4924 or C1
treatment, MLL-AF9 protein level increased in THP-1 cells under these
two conditions (Fig. 5A). CKS protein levels were also aﬀected; there
was an increase in total CKS protein in all cases, except in THP-1 cells
treated with MLN4924 (Fig. 5A).
When THP-1 and KOPN-8 cells were challenged with C1 or
MLN4924, both cell lines showed signiﬁcant reductions in cell viability
compared to cells treated with DMSO (vehicle), or CD34+ and PBMCs
from healthy donors (Fig. 5B). These results appear to contradict those
obtained via RNA interference (i.e. showing no variation in cell viabi-
lity), but this discrepancy is most likely explained by the incomplete
knockdown, as previously stated (Fig. S7). To conﬁrm the drug sensi-
tivity of these cell lines when compared to healthy controls, clonogenic
assays were performed. Colony formation of MLLr AML lines was re-
duced following C1 or MLN4924 treatment, compared to the vehicle
control, whereas CD34+ colony formation remained unaﬀected (Fig.
S8). The reduction in THP-1 cell viability correlated with a signiﬁcant
increase in apoptotic cells (Annexin V positive; Fig. 5C) and activation
of Caspase 3 (Fig. S9) for both C1 and MLN4924. Surprisingly, while the
KOPN-8 cells showed increased apoptosis after C1 treatment, MLN4924
caused cell cycle-arrest in G1 or G2 phase, devoid of cells progressing
through S-phase (Fig. 5D and Fig. S9). We tested two additional cell
lines: ML-1, an AML cell line expressing MLL-AF6, and RS4;11, an ALL
cell line expressing MLL-AF4. Interestingly, both responded to the in-
hibitor C1, whereas MNL4924 treatment induced cell death only in the
ML-1 cell line (Fig. S10). Thus, eﬀective targeting of the neddylation
pathway using MLN4924 seems to be restricted to MLLr AML lines,
while bothMLLr AML andMLLr ALL lines appear to be sensitive to C1 at
doses which exhibit low toxicity in healthy cells.
Altogether, these results indicate that Cullin-based protein de-
gradation is important for MLL-translocation cell viability, and a range
of SKP2-CKS1 targets, the MLL-FPs themselves included, may be in-
volved in ﬁne-tuning this process.
4. Discussion
Previous studies, describing the requirement of Cks1 [8,47] and
Cks2 [8,13] in cell cycle dynamics, have postulated that targets of the
Cks1/Cks2 axis may extend beyond the speciﬁc subset of Cyclins and
CKIs [5,7,10,13,62]. Here, we provide the ﬁrst evidence for an essential
role of the Cks1/Cks2 axis in the regulation of Mll1 expression. The
divergent roles Cks1 and Cks2 play in Mll1 stability have major
downstream consequences on the Wnt signalling pathway. We also
identiﬁed an impact on MLLr cell viability when interfering with the
CKS1/CKS2 axis.
We demonstrated the requirement of Cks1 and Cks2 in Mll1 protein
expression throughout the cell cycle. Interestingly, knockout of Cks1
mimics the stable Mll1 protein levels previously described in leukaemia
[30], while knockout of Cks2 has the opposite eﬀect, with Mll1 protein
levels almost undetectable. The downstream eﬀect of MLL1 stabilisa-
tion (as observed in Cks1−/− MEFs) has been well documented in MLLr
leukaemia [28,30,31,63,64], in which the normal epigenetic proﬁle
and cooperating signalling pathways, governed by MLL1, are hijacked
by MLL-FPs [48,65–69]. One key downstream pathway is the Wnt/β-
catenin pathway, which is involved in both primary mixed-lineage
leukaemia development [45,49,50] and drug resistance [70,71]. Whilst
the bone marrow niche is the primary provider of extracellular Wnt
signals required for both haematopoietic stem cell and leukaemic stem
cell self-renewal [51,72–74], MLL1 and MLL-FPs play critical roles in
intracellular regulation of Wnt signalling [52,75–77]. Therefore, the
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Mll1-dependent impact of the Cks1/Cks2 axis on Wnt signalling is of
particular interest. The Wnt signalling changes that we observed in Cks-
deﬁcient MEFs are consistent with those reported in both the Skp2−/−
[74] and p27−/− [78–80] mouse models, indicating that Cks1/Cks2/
SCFSkp2 dynamics are likely responsible for these alterations. Interest-
ingly, CKS1B (Myc-dependent) [14] and CKS2 [81] expression can also
be regulated by the Wnt signalling eﬀector β-catenin, forming a feed-
back loop mediated through the CKS1/CKS2 axis, which may be re-
quired to balance intracellular Wnt signalling, in response to both in-
ternal and external stimuli. In cases in which Wnt signalling is
responsible for the emergence of leukaemic stem cells that are resistant
to key therapeutic agents [49,70,71], the regulation of Mll1, and con-
sequently Wnt signalling, by the CKS1/CKS2 axis provides a positive
new alternative for combating these leukaemic stem cells and keeping
Wnt signalling under control.
Overexpression of CKS1B and CKS2 has been documented in a
variety of cancers [6,16,18–23,82], downstream of a variety of onco-
genes, and their high expression has been correlated with poor prog-
nosis. Similarly, CKS1B expression has been reported to be high in CML
patients at blast crisis and, further to this, signiﬁcantly reduced after
imatinib (STI-571) treatment [47]. Investigation of Cks1 roles in the Eμ-
Myc lymphoma mouse model indicates that Cks1 functions in cancer
expand beyond p27 regulation, and other pathways may be regulated
by Cks1 [14]. We found that MLLr leukaemic blasts have upregulation
of CKS1B and CKS2 compared to terminally diﬀerentiated cells
(PBMCs), and further increase CKS1B expression in CD34+ cells, a
ﬁnding further conﬁrmed in the MILE study [46]. This suggests that
CKS-upregulation could be a signiﬁcant factor in these cancer cells.
Higher expression of CKS1B and CKS2 in leukaemic cells, compared to
terminally diﬀerentiated cells, may be an important part of the epige-
netic re-programming of normal blood cells to block diﬀerentiation and
increase the number of more stem-like leukaemic cells by MLL-FPs
[28,64,83–85]. Furthermore, high levels of CKS1B observed in hae-
matopoietic stem and progenitor cells (CD34+) indicate that CKS1B
may be a central factor of the stem cell program hijacked by MLL-FPs in
MLLr leukaemia.
The variety of leukaemogenic MLL-FPs reported produce a hetero-
geneous disease, dependent on the FP present [28,86]. This hetero-
geneity was reﬂected in the presence or absence of interactions with
CKS1 and/or CKS2, depending on the respective MLL-FPs that we in-
vestigated. Despite a lack of interaction between CKS1/2 and MLL-ENL,
Wnt signalling was still aﬀected in MLL-ENL cells following CKS1 and/
or CKS2 knockdown. A probable explanation is that CKS1/2 are dis-
placed in the larger COMPASS-like complex [28] built by MLL-ENL,
which might impact on additional downstream functions. Although
Cks1/2 was shown to interact with MII1 (N- and C-terminal subunits),
interaction between CKS1/2 and the fusion partner or the wild-type
copy of the fusion partner cannot be excluded. Further to this, stabili-
sation of the WT MLL1 protein in MLL-FP cells may play a crucial role
in combating aberrant MLL-FP epigenetic functions [36]. Disrupting
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MLL-FP transcriptional complexes is perceived to be a promising route
for eradicating aggressive mixed-lineage leukaemias [28,37,63], and
our discovery of new MLL-FP complex interactions may provide new
druggable targets.
As previously reported for p27 [8], Cks1 constrains Mll1 function by
promoting its degradation, while Cks2 stabilises Mll1. The fact that
both CKS1 and CKS2 are often overexpressed in primary cancers and
tumour-derived cell lines suggests that neoplastic cell proliferation
depends on a carefully balanced signalling network in which both
proteins partake. Therefore, the promise of ubiquitin ligase inhibitors in
combating tumour cell growth can be rationalised by their impact on
this signalling network, such that it no longer supports uncontrolled cell
proliferation.
The clinical utility of inhibiting protein degradation in leukaemia,
and more speciﬁcally the Cullin-RING ligase family, is currently the
focus of clinical trials (NCT00911066 and NCT01814826). Use of the
NAE inhibitor MLN4924 indicates that inhibition of Cullin-RING ligases
is eﬀective in targeting mixed-lineage leukaemia [60,87], however,
resistant cells arise upon treatment [88]. The SCFSkp2-Cks1 complex is
one constituent of the Cullin-RING ligase family, speciﬁcally targeting a
small range of proteins within the larger range of pan-Cullin mediated
degradation [89–91]. The new generation of inhibitors targeting the
SCFSKP2-CKS1 complex provides a more speciﬁc and sensitive treatment,
which may reduce oﬀ-target eﬀects [57,58,92]. Currently, therapies
targeting epigenetic functions of MLL-FPs, including BET [70,71,93]
and DOT1L [94] inhibitors, produce satisfactory results initially, but
resistance emerges due to transcriptional plasticity [70,71,95,96]. Our
data suggest that CKS-inhibiting agents, in combination therapy, might
be able to eradicate both quiescent leukaemic stem cells, and resistant
proliferating clones. Indeed, while it is anticipated that p27 modula-
tion, promoting cell death, would be similar in all leukaemic cells, the
dysregulation of the Wnt pathway may be more pronounced in vivo.
The Wnt pathway is crucial for various leukaemic stem cell (LSC) fea-
tures involved in LSC drug resistance (e.g. survival and tumour-niche
communication), indicating that inhibiting CKS proteins may have a
dual purpose in leukaemic survival, targeting both p27 and Wnt sig-
nalling.
The emergence of new inhibitors targeting alternative functions of
the CKS1/CKS2 axis [97] provides great promise. Future studies will be
needed to fully understand the molecular dynamics and downstream
functions of the CKS1/CKS2/SKP2 pathway as new players are still
being identiﬁed [98,99], and in vivo studies will be required to validate
their therapeutic potential.
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